CL2025002035A1 - Compuestos moduladores de receptores de dopamina d3/d2 - Google Patents

Compuestos moduladores de receptores de dopamina d3/d2

Info

Publication number
CL2025002035A1
CL2025002035A1 CL2025002035A CL2025002035A CL2025002035A1 CL 2025002035 A1 CL2025002035 A1 CL 2025002035A1 CL 2025002035 A CL2025002035 A CL 2025002035A CL 2025002035 A CL2025002035 A CL 2025002035A CL 2025002035 A1 CL2025002035 A1 CL 2025002035A1
Authority
CL
Chile
Prior art keywords
compounds
receptors
modulate dopamine
formula
dopamine
Prior art date
Application number
CL2025002035A
Other languages
English (en)
Spanish (es)
Inventor
Borza István
Éles János
MENCZINGER Bálint
BODNÁRNÉ DÉAK Szilvia
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of CL2025002035A1 publication Critical patent/CL2025002035A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2025002035A 2023-01-11 2025-07-09 Compuestos moduladores de receptores de dopamina d3/d2 CL2025002035A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363479530P 2023-01-11 2023-01-11

Publications (1)

Publication Number Publication Date
CL2025002035A1 true CL2025002035A1 (es) 2025-10-03

Family

ID=89573273

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025002035A CL2025002035A1 (es) 2023-01-11 2025-07-09 Compuestos moduladores de receptores de dopamina d3/d2

Country Status (13)

Country Link
US (2) US12168007B1 (enExample)
EP (1) EP4400495A1 (enExample)
JP (2) JP7686096B2 (enExample)
CN (1) CN120569367A (enExample)
AR (1) AR131577A1 (enExample)
AU (1) AU2024208533A1 (enExample)
CL (1) CL2025002035A1 (enExample)
CO (1) CO2025010725A2 (enExample)
GE (1) GEAP202516807A (enExample)
IL (1) IL321654A (enExample)
MX (1) MX2025008101A (enExample)
TW (1) TW202432139A (enExample)
WO (1) WO2024150068A2 (enExample)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
EP1870405A1 (en) 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
US8686009B2 (en) 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
WO2020156312A1 (zh) 2019-01-30 2020-08-06 江苏豪森药业集团有限公司 一种多环类衍生物调节剂、其制备方法和应用
CN118772126A (zh) 2019-10-29 2024-10-15 上海翰森生物医药科技有限公司 四元环类衍生物调节剂、其制备方法和应用
WO2021088920A1 (zh) 2019-11-05 2021-05-14 上海翰森生物医药科技有限公司 苯并噻吩类衍生物调节剂、其制备方法和应用

Also Published As

Publication number Publication date
JP7686096B2 (ja) 2025-05-30
KR20240112213A (ko) 2024-07-18
TW202432139A (zh) 2024-08-16
CN120569367A (zh) 2025-08-29
JP2024098972A (ja) 2024-07-24
JP2025122072A (ja) 2025-08-20
US12168007B1 (en) 2024-12-17
GEAP202516807A (en) 2025-08-25
US20250049786A1 (en) 2025-02-13
WO2024150068A3 (en) 2024-08-22
WO2024150068A2 (en) 2024-07-18
IL321654A (en) 2025-08-01
MX2025008101A (es) 2025-08-01
AU2024208533A1 (en) 2025-07-10
CO2025010725A2 (es) 2025-08-29
AR131577A1 (es) 2025-04-09
EP4400495A1 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
CO2020013601A2 (es) Compuestos heterocíclicos como inmunomoduladores
DOP2022000117A (es) Inhibidores de kras g12c
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
CO2018011064A2 (es) Inhibidores de bromodominios
CL2019000368A1 (es) Inhibidores de cdk2/4/6.
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
UY27884A1 (es) Moduladores del receptor de glucocorticoides
CL2019001264A1 (es) Ácidos propiónicos 3-sustituidos como inhibidores de la integrina alfa v.
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
CU20210035A7 (es) Compuestos de azalactam como inhibidores de hpk 1
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
DOP2011000110A (es) “derivados de bencimidazol n3 alquilados como inhibidores de mek”
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
CL2020003065A1 (es) Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
CL2021001461A1 (es) Moduladores de trex1
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
NZ713589A (en) Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
CO2021013166A2 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
MX2021002260A (es) Compuestos utiles como moduladores de la autofagia mediada por chaperonas.
MX2018007432A (es) Compuestos de dihidroquinolinsulfonamida de alquilo.
DOP2024000165A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
HN2011000404A (es) Derivados de enfumafungina y composicion comprendiendo los mismos